Beverly, MA – According to filings with the U.S. Securities and Exchange Commission, Akston Biosciences is raising $10,000,088.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Todd Zion played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Akston Biosciences

Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the worlds first clinical glucose-responsive insulin at SmartCells, Inc., Akstons COVID-19 vaccine candidate is in Phase II trials in the Netherlands. It has partnered with Dechra Pharmaceuticals PLC to commercialize once-a-week canine and feline insulin therapies. The company employs 35 people, has over 3,500 ft2 of research laboratory space and a 12,400 ft2 GMP clean room biologics manufacturing facility.

To learn more about Akston Biosciences, visit http://www.akstonbio.com/

Contact:
Todd Zion, President and Chief Executive Officer
978-969-3381
todd.zion@akstonbio.com
https://www.linkedin.com/in/todd-zion-6b85ab1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved